What are current best practices on holding metformin prior to and post . . . Contrast-induced acute kidney injury (CI-AKI) is a serious complication of iodinated contrast medium (CM) administration 1 In recent years, there has been a marked rise in the use of CM in diagnostic and interventional procedures 2 Contrast-induced AKI is consequently the third most common cause of hospital-acquired AKI, accounting for
Prevention of contrast-induced acute kidney injury . . . - UpToDate AKI that is judged to be caused by iodinated contrast material (ie, after exclusion of other possible etiologies) has historically been called contrast-induced nephropathy (CIN) but has since been termed contrast-induced AKI (CI-AKI)
Metformin, arterial contrast and acute kidney injury - PMC CIN or AKI after contrast exposure was defined as more than 25% rise in serum creatinine levels from baseline at 48 hours after contrast exposure absolute rise in creatinine by 0 5 mg dL (2)
Metformin Can Be Safely Used in Patients Exposed to Contrast Media: A . . . Conclusion: Metformin can be safely used in patients with moderate renal impairment (eGFR ≥ 30 mL min 1 73 m 2) during CM exposure Contrast-induced acute kidney injury (CI-AKI) has been identified to be a major healthcare problem
Metformin and contrast-induced acute kidney injury in diabetic patients . . . To analyze the association between chronic metformin treatment and the development of contrast-induced acute kidney injury (CI-AKI) after primary percutaneous coronary intervention (PCI) for ST segment elevation myocardial infarction (STEMI)
Post-contrast acute kidney injury. Part 2: risk stratification, role of . . . Topics reviewed include stratification of PC-AKI risk, the need to withdraw nephrotoxic medication, PC-AKI prophylaxis with hydration or drugs, the use of metformin in diabetic patients receiving contrast medium and the need to alter dialysis schedules in patients receiving contrast medium